Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Drugs, Nonprescription --- Nonprescription drugs --- OTC drugs --- Over-the-counter drugs --- Drugs --- Health products --- Nonprescription drug industry --- Patent medicines --- Government policy

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Traditional medicines have and will continue to form the basis of modern pharmaceuticals. Many indigenous communities are claiming rights in pharmaceuticals derived from their traditional medicine. In the past, such knowledge derived from non-western communities was largely regarded as free information. This has led some to attack the patent system as an ex-ploitative tool of the developed world. The first part of this analysis deals with the kind of protection provided in national legislation. Methods of protecting traditional medicine in India and China receive special attention. The second major issue covered in this volume is the kind of protection offered to TM of other countries in the west, including international agreements. America is a particular focus, as it is here that many of the battles over patenting traditional medicine are fought. While no uncon-troversial answers can be given in this debate, at least the relative strengths and weaknesses of various positions can be assessed. Dr. Murray Eiland received a doctorate in Oriental Archaeology from Oxford University and an LLM from the Munich Intellectual Property Law Center. He currently works at Charles Henry & Co., London as a (non-practising) Barrister.

Patent medicines. --- Patents (International law) --- Patent laws and legislation (International law) --- International law --- Medicines, Patent, proprietary, etc. --- Proprietary drugs --- Proprietary medicines --- Drugs --- Drugs, Nonprescription

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

"This book is an outcome of a partnership between the Max Planck Institute (MPI) for Innovation and Competition and the South Centre, which jointly organized a Global Forum on Intellectual Property, Access to Medicine and Innovation in Munich on 9-10 December 2019"--Page v

Patent medicines --- Law and legislation --- Medicines, Patent, proprietary, etc. --- Proprietary drugs --- Proprietary medicines --- Drugs --- Drugs, Nonprescription --- access to medicines --- TRIPS --- Intellectual Property Exhaustion --- Compulsory license --- Pharmaceutical Patents --- genome editing --- Open Access

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

In this book, the ownership, distribution and sale of patent medicines across Georgian England are explored for the first time, transforming our understanding of healthcare provision and the use of the printed word in that era. Patent medicines constituted a national industry which was largely popular, reputable and stable, not the visible manifestation of dishonest quackery as described later by doctors and many historians. Much of the distribution, promotion and sale of patent medicines was centrally controlled with directed advertising, specialisation, fixed prices and national procedures, and for the first time we can see the detailed working of a national market for a class of Georgian consumer goods. Furthermore, contemporaries were aware that changes in the consumers’ ‘imagination’ increased the benefits of patent medicines above the effects of their pharmaceutical components. As the imagination was altered by the printed word, print can be considered as an essential ingredient of patent medicines. This book will challenge the assumptions of all those interested in the medical, business or print history of the period.

Patent medicines --- History. --- History --- Medicines, Patent, proprietary, etc. --- Proprietary drugs --- Proprietary medicines --- Drugs --- Drugs, Nonprescription --- Medicine. --- Great Britain-History. --- Law-History. --- History of Science. --- History of Medicine. --- History of Britain and Ireland. --- Legal History. --- Clinical sciences --- Medical profession --- Human biology --- Life sciences --- Medical sciences --- Pathology --- Physicians --- Annals --- Auxiliary sciences of history --- Health Workforce --- Medicine—History. --- Great Britain—History. --- Law—History.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book investigates lifecycle management strategies used by pharmaceutical companies attempting to maximize the value of their product portfolio. Such strategies are sometimes referred to by generic drug companies as “evergreening”. The analysis focuses on two of these strategies, namely product improvements and product line extensions. In particular, an evaluation of the patents that follow the basic one and that accompany the development of a drug from research to market is attempted. Two “blockbuster” drugs, Taxotere and Xalatan, were randomly chosen to carry out such analysis. The patent portfolio of the originator companies is outlined and some important patents for each area of research (e.g. formulations, combinations, delivery devices) are shortly described. Patent filing trends for the two drugs, both in regards of the originator and in regards of other competing companies (amongst these also the generics) are schematically shown.

Patent medicines --- Drugs --- Law and legislation --- Economic aspects --- Medicines, Patent, proprietary, etc. --- Proprietary drugs --- Proprietary medicines --- Drugs, Nonprescription --- Medicaments --- Medications --- Medicine (Drugs) --- Medicines (Drugs) --- Pharmaceuticals --- Prescription drugs --- Bioactive compounds --- Medical supplies --- Pharmacopoeias --- Chemotherapy --- Materia medica --- Pharmacology --- Pharmacy --- Markenrecht --- Urheberrecht / Gewerblicher Rechtsschutz und Medienrecht --- Gewerblicher Rechtsschutz